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Abstract
Peripheral neuropathy (PN) is the most frequent neurological complication in people living with HIV/AIDS. Neurological
damage was identified to not only be caused by the viral infection itself but also through neurotoxic antiretroviral therapy
(ART). PN is associated with a variety of risk factors; however, detailed knowledge is scarce for sub-Saharan African popula-
tions, bearing among the highest HIV/AIDS infection burden.
In a cross-sectional study, we assessed the prevalence of PN in 525 adult outpatients suffering fromHIV/AIDS and admitted to
the largest tertiary hospital in Ghana. Through a detailed questionnaire and clinical examination including neurologic assessment
and laboratory blood sample testing, this study investigated associations of PN with demographic and health determinants and
identified risk factors associated with sensory neuropathy.
The prevalence of PN in the Ghanaian cohort was 17.7% and increased odd ratios (OR) when patients were taller (> 1.57 m;
OR = 3.84; 95% CI 1.38–10.66) or reached the age > 34 years (p = 0.124). Respondents with longer education duration had
significantly less PN (≥ 9 years of education; OR = 0.49; 95% CI 0.26–0.92). The study also identified significant association of
PN to both waist and hip girth and neutrophil counts. Curiously, higher adjusted odd ratios (aOR) of PN of patients under ART
treatment were observed when CD4 lymphocytes were elevated (aOR = 0.81; 95% CI 0.36–1.83 and aOR = 2.17; 95% CI 0.93–
5.05, for 300 and 600 counts, respectively). For patients on ART, an increase of 10 CD4 cell count units increased their chance of
developing PN by 1% (aOR = 1.01; 95% CI 1.00 to 1.03).
Despite current drug application regulations, prevalence of PN is still unacceptably high in sub-Saharan African populations.
Reduction in chronic morbidity through a health system with routine monitoring, early diagnosis and prompt intervention, and
effective case management can improve people living with HIV/AIDS’ quality of life.
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Introduction
Peripheral neuropathy (PN) in its diverse forms has been re-
ported as the most frequent neurological disorder found in
patients with human immunodeficiency viral infection
(Keswani et al. 2002; Morgello et al. 2004; McArthur et al.
2005; Ellis et al. 2010). Damage of the nerve fibers caused by
the virus first appears in the lower extremities, impedes sen-
sory capacity and mobility and is often painful (Harrison and
Smith 2011; Cherry et al. 2012). Impairment in quality of life
is often underestimated and the adverse change in lifestyle
often culminates in psychological impact including depres-
sion (Griswold et al. 2005; Robinson-Papp et al. 2010;
Shaikh et al. 2013; Phillips et al. 2014; Pillay et al. 2018).
Sadly, PN was not only shown to be associated with HIV
infection itself but also in many cases triggered by the respective
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treatment with antiretroviral agents (Keswani et al. 2002;
Cornblath and Hoke 2006; Cherry et al. 2012; Schutz and
Robinson-Papp 2013; Margolis et al. 2014). The introduction
of antiretroviral therapy (ART) has led to significant worldwide
reduction of morbidity and mortality caused by HIV/AIDS
(Scanlon and Vreeman 2013; UNAIDS 2016). Recommended
as initial treatment are nucleoside reverse-transcriptase inhibitors
(NRTIs), followed by integrase strand transfer inhibitors, and
boosted by protease inhibitors or combinations thereof
(Kamerman et al. 2015;Gunthard et al. 2016). Growing evidence
of occurring unwanted side complications through exposure to
thesemedications has led to increasing use of safer ART inmany
countries (World Health Organisation 2015; Ngassa Mbenda
et al. 2017).
Still, PN remains prevalent as the most common neurological
disorder among people living with HIV/AIDS (PLHIV). A num-
ber of studies show that HIV-PN is experienced by 30–60% of
PLHIV, surely counting up to several millions of affected world-
wide (Ferrari et al. 2006; Evans et al. 2008; Ghosh et al. 2012;
Kamerman et al. 2012; Cherry et al. 2016). Albeit rates of sensory
neuropathies among HIV patients were reported particularly high
in African cohorts (Boulle et al. 2007; Forna et al. 2007; Hawkins
et al. 2007; Hoffmann et al. 2008; Mehta et al. 2010), PN is both
underdiagnosed and undertreated in low- and middle-income
countries. Owing to the fact that sub-Saharan Africa has the
highest population of affected PLHIV, scarce PN prevalence data
from the African continent indicates a large underrepresentation of
research including these population groups (Kamerman et al.
2012; Arenas-Pinto et al. 2016; Ngassa Mbenda et al. 2017).
This study was performed in the largest tertiary referral
hospital in Ghana, West Africa, between 2013 and 2014. To
our knowledge, this is the first investigation of PN prevalence
among PLHIV in Ghana. From our routine clinical manage-
ment of HIV-PN patients admitted to the health facility, we
had strong presumptions on (i) a relatively high prevalence of
PN developing in PLHIV, (ii) an association with the medica-
tion given in accordance with the guidelines of the National
AIDS Control Programme regulations, and (iii) we had as-
sumptions, but no information, on health determinants being
associatedwith PN onset among the patients attending. Once a
diseased person develops the condition of a sensory disorder,
clinicians face challenges to manage the case, and prevention
of PN would both decrease disability and lower the costs of
local health care. Therefore, in this study, we (i) sought to
quantitatively determine PN prevalence among PLHIV at the
referral health facility in Ghana, (ii) determine associations of
PN development with demographic and health determinants,
and (iii) identify and confirm potential risk factors, including
ART, in a West African setting.
For this, we studied parameters in a cohort of PLHIV de-
veloping PN including demographic parameters, anthropo-
genic variables, behavioral aspects, and clinical findings. PN
manifestation was assessed through quantitative measurement
applying the biothesiometer instrument, and blood samples
were collected from the study subjects for downstream analy-
sis of laboratory parameters.
Methods
Study design
For this work, a hospital-based cross-sectional study was con-
ducted at the Korle-Bu Teaching Hospital (KBTH) in Accra,
the largest tertiary hospital in Ghana, with a capacity of 2000
beds and an outpatient department attendance of over 350,000
in 2016. Patients were recruited from the adult HIVoutpatient
clinic at the infectious disease unit attending about 19,000
PLHIV at the time of the study, 7000 of which being on
ART. Out of the pool of regular attendants to the outpatient
clinic, the study population was recruited. Patients were in-
formed on objectives and goal of the study, and informed
consent was sought for each participant in written form for
involvement in the study. Inclusion criteria encompassed
adults with more than 18 years of age who regularly attend
the infectious disease unit and were diagnosed with HIV-
AIDS. Diagnosis of HIV was made at the infectious unit by
antibody detection on blood samples followed by laboratory
confirmation using the OraQuick test according to the Ghana
National AIDS Control Programme guidelines. A participant
was declared positive for HIV if both tests were positive. The
sample size was estimated using StatCalc (Epi Info 2002)
computer software considering the following parameters: (i)
population size of Greater Accra~2,500,000, (ii) expected a
frequency of HIV-PN = 5%, and (iii) worst acceptable result =
1%. StatCalc yielded a sample size of 114 at a confidence
level of 95%. Assuming 20% (i.e., 23) non-participation/
non-response, the total sample size then would be 114 +
23 = 137. An extra number of 163 patients were added to
make a total of at least 300. Participants were recruited by
systematic random sampling with five patients per day invit-
ing the first patient of each full hour. None of the patients
which were sought for enrollment declined consent.
Altogether, 525 HIV-positive patients were recruited to partic-
ipate in the study between 2013 and 2014.
Collection of socio-demographic and clinical data
Following informed written consent, a questionnaire was ad-
ministered by a trained research assistant to the participant in
order to systematically obtain the following information: sex,
age, level of education, employment status, and alcohol and
tobacco consumption. Consequently, participants underwent
clinical examination to ascertain information on diabetes, hy-
pertension, and any history thereof. Anthropogenic
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measurements were taken to document height, weight, hip
girth, and waist girth.
Biothesiometric examination
As part of the physical examination, the use of a
biothesiometer was applied in order to diagnose PN as objec-
tively as possible. A handheld biothesiometer (BioMedical
Instruments, Newbury, OH, USA) which vibrates at 100 Hz
when operating on 50 Hz mains was applied to measure the
vibration perception threshold (VPT) to determine neurologi-
cal deficits and for which we expected both specificity and
sensitivity of above 70% (Yajnik et al. 2012; Gill et al. 2014).
Impaired VPTwas measured in three recordings on the plantar
aspect of the distal phalanx of the big toe. Each participant was
seated in a comfortable and relaxed position and was made to
feel the vibration sense of the biothesiometer and to report the
initial feel by saying Byes^. The device was held steadily over
the testing site such that the weight of the vibrator exerts a
standard pressure. The amplitude of the vibration was gradu-
ally increased from zero to a maximum of 50 V. For partici-
pants who were unable to feel any vibration even at the max-
imum amplitude, the value of 50 V was recorded. In order to
circumvent usage variation and interpretation of the
biothesiometer by different physicians, training on the device
was given prior to the onset of the investigation. AVPT value
of > 9 V was defined as the manifestation of PN.
Laboratory analysis
Fasting blood samples were collected from each participant
for further laboratory analysis at a local commercial laboratory
facility. Blood was tested for lipoprotein, lactate, hemoglobin,
and fasting glucose. CD4 leukocytes were counted, as were
neutrophils.
Data entry
Documentation of the study included the study protocol, the
investigators’ log sheet, the patients’ log sheet, the informed
consent, and the questionnaire. From the paper-based and
filled case report form, data were entered into the Epi Info
software and combined with data retrieved from laboratory
analyses. Captured data per participant was cleaned and data
transfer periodically checked by trained personnel, followed
by application of blinding methodology. Subsequently, data
entry of 53 (10%) randomly selected subjects of the 525 pa-
tient documentations was reproduced by a person that was
neither involved in the study nor in data entry. Among those,
only two parameters of the whole raw data set differed which
had no impact on the analysis. This random test confirmed the
reliability of the entire data set for further analysis.
Statistical analysis
Continuous factors were summarized as means and standard
deviations and categorical factors as counts and proportions.
Categorized data were additionally analyzed using underlying
continuous values in order not to reduce statistical power.
Medians and interquartile ranges were also calculated but are
not presented. In order to examine the association between po-
tential risk factors of PN, firstly, unadjusted comparisons were
calculated. Unadjusted comparisons were done using a Chi-
square test or Fisher’s exact test if the parameter was categorical,
and theMann-WhitneyU test if the parameterwas continuous. In
a second step, multivariable logistic regressions were performed
to determine the associations between PN as a binary variable
and potential risk factors. Factors known from the literature to
have an association with PN and factors with an unadjusted
association at p < 0.20 were included in the initial multivariable
model. The risk factors included in the initial model were being
on ART, change of ART medication, patient’s sex and age, edu-
cation, height and height to weight ratio, hip and waist girth,
lactate, chromium concentration, neutrophils and lymphocytes,
and CD4 cell counts. The model was reduced using backwards
selection with a threshold alpha of 0.25. The statistical software
SAS version 9.4 (2002–2012, SAS Institute Inc., Cary, NC,
USA) was used to perform the analysis. Statistical significance
was set to an alpha level of 0.05. The dataset was not complete
for all parameters throughout the 525 subjects, and therefore,
almost one-third of the subjects could unfortunately not be in-
cluded in the multivariable analyses. In a sensitivity analysis, in
order to examine the effect of the absence of those respondents,
inverse probability weights were calculated and included in the
logistic regression, and results were compared to those from the
main analysis.
Results
A total of 525 HIV-positive study participants were recruited for
the study. Four hundred and thirty-seven (84.4%) were female;
81 (16.6%) were male. The mean age was 33.6 ± 4.9 with the
minimum and maximum age of 19 and 40, respectively. Results
are outlined in Table 1 including education and employment
status, behavioral aspects (consumption of alcohol and tobacco),
and bodymeasurements (height, weight, and hip andwaist girth).
The mean BMI was calculated as 23.9 ± 4.9 and ranged from
11.3 to 44.6 (not shown). Table 1 also lists laboratory measures
encompassing CD4 cell counts, lipoprotein, lactate, hemoglobin,
and fasting glucose values.
Of the 525 respondents, 314 (59.8%) were on ART. Out of
these 314 patients on ART, 281 could give information on the
duration on ART, ranging between 1 to 248 months and with the
mean of 39.9 ± 30.4 months. Table 2 shows the ART regimen
groups administered to the enrolled patients. The prevalence of
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PN among study participants was 17.7%—93 of the 525 subjects
were diagnosed with the neurological disorder above the VPT
using the biothesiometer. Of the 93 respondents with diagnosed
PN, 50 were on AR therapy and 43 were not.
Table 3 outlines, in an unadjusted manner, potential associa-
tion between PN and anthropometric, socioeconomic, and clini-
cal characteristics of HIV-positive respondents. Factors of statis-
tical significance (p< 0.05) towards development of PN include
Table 1 Socio-demographic and clinical characteristics: distribution of patients with HIVat a tertiary hospital in Ghana, stratified by receiving ARTor
not
Characteristic Total (n = 525)
n (%)
On ART (n = 314)
n (%)
Not on ART (n = 211)
n (%)
p value*
Sex < 0.001
Male 81 (15.6) 34 (11.0) 47 (22.6)
Female 437 (84.4) 276 (89.0) 161 (77.4)
Age (mean ± SD) 33.6 ± 4.9 34.6 ± 4.3 32.0 ± 5.4 < 0.001
Education 0.019
None 88 (17.1) 61 (19.7) 27 (13.1)
≤ 9 years 253 (49.0) 154 (49.7) 99 (48.1)
9–12 years 123 (23.8) 72 (23.2) 51 (24.8)
> 12 years 50 (9.7) 21 (6.8) 29 (14.1)
Others 2 (0.4) 2 (0.7) 0 (0)
Employment status 0.302
Unemployed 104 (20.5) 62 (20.5) 42 (20.6)
Part-time 22 (4.3) 14 (4.6) 8 (3.9)
Full-time employment 365 (72.0) 221 (72.9) 144 (70.6)
Retired and not working 0 (0) 0 (0) 0 (0)
Retired but working 1(0.20) 0 (0) 1 (0.5)
Lost employment when status
was discovered
1 (0.20) 1 (0.33) 0 (0)
Too weak to continue working 14 (2.8) 5 (1.7) 9 (4.4)
Alcohol consumption < 0.001
Yes, currently 52 (10.0) 14 (4.5) 38 (18.2)
No 469 (90.0) 298 (95.5) 171 (81.8)
Smoking status 0.209
Current smoker 10 (1.9) 4 (1.3) 6 (2.9)
Non/ex-smoker 512 (98.1) 309 (98.7) 203 (97.1)
Height (cm, mean ± SD) 162.7 ± 8.0 161.8 ± 7.9 163.9 ± 8.1 0.002
Weight (kg, mean ± SD) 63.5 ± 13.4 64.1 ± 13.0 62.6 ± 14.0 0.172
Hip girth (cm, mean ± SD) 79.1 ± 30.8 89.8 ± 25.3 63.7 ± 31.5 < 0.001
Waist girth (cm, mean ± SD) 66.8 ± 27.0 73.3 ± 22.0 53.4 ± 27.7 < 0.001
Peripheral neuropathy 0.201
Yes 93 (17.7) 50 (15.9) 43 (20.4)
No 432 (82.3) 264 (84.1) 168 (79.6)
CD4 cell count (mean ± SD) 448.2 ± 271.8 493.1 ± 255.7 385 ± 281.8 < 0.001
Low-density lipoprotein (μmol/l, mean ± SD) 3.1 ± 0.9 3.3 ± 0.9 2.9 ± 0.9 < 0.001
High-density lipoprotein (μmol/l, mean ± SD) 1.3 ± 0.4 1.5 ± 0.4 1.1 ± 0.3 < 0.001
Lactate (mmol/l, mean ± SD) 1.8 ± 0.4 1.7 ± 0.4 1.9 ± 0.3 < 0.001
Hemoglobin (g/dl, mean ± SD) 11.9 ± 1.7 12.0 ± 1.6 11.8 ± 1.8 0.049
Fasting glucose (mmol/l, mean ± SD) 4.7 ± 0.6 4.7 ± 0.7 4.7 ± 0.5 0.800
*Chi-square or Fisher’s exact test was used if characteristic was categorical and Mann-Whitney U test if continuous
ART, antiretroviral therapy; SD, standard deviation
Peripheral neuropathy = vibration perception threshold > 9 V, base of first toe (left and right; average of three measurements)
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(i) body height, (ii) waist girth, (iii) hip girth, (iv) neutrophil
counts, (v) lymphocyte counts, and (vi) chromium level.
Multivariable analyses of PN with ART and other risk fac-
tors are shown in Table 4. Re-analyses of the data on height
and age using continuous variables give the same results.
Surprisingly, the study found a significant association be-
tween being on ART and CD4 cell counts (p = 0.007). In the
presence of an interaction, both antiretroviral (AR) medication
and CD4 cells had an effect on PN development (p = 0.066 and
p = 0.033, respectively). For patients on ART, an increase of 10
CD4 cell count units increased their chance of developing PN by
1% (adjusted odd ratio (aOR) = 1.01; 95% CI 1.00 to 1.03). In
contrast, for patients not on ART, such increase of 10 units in
CD4 cell counts decreased their chance of developing PN by 2%
(aOR= 0.98; 95% CI 0.97 to 1.00) (Table 4). Figure 1 visualizes
this interaction between developing PN and being on ART. The
aOR are as follows: 0.69 (95%CI 0.29–1.64) at a CD4 cell count
of 250; 1.33 (95%CI 0.63–2.81) at a CD4 cell count of 450; and
2.17 (95% CI 0.93–5.05) at a CD4 cell count of 600. Hence, the
probability of being diagnosedwith PN—when being onARTor
not—in relation to CD4 cell counts could be estimated (Fig. 1).
Statistical significance towards developing PNwas also found
to be associated with an increase in lactate levels (p= 0.073) and
with age over 34 years (p = 0.124). Instead, patients with >
9 years of education have a lower risk of suffering PN (p =
0.027). With a statistically significant overall effect of body
height on PN (p = 0.007), study participants between 1.57–
1.62 m of height had 3.84 times the aOR of developing PN
compared to those with heights ≤ 1.57 cm (95%CI 1.38 to
10.66). This aOR increases to 4.89 and 5.74 times the aOR of
subjects between 1.62–1.66 m (95% CI 1.69 to 13.66) and >
1.66 m (95% CI 2.11 to 15.62), respectively.
No statistical significance among PLHIV with PN was found
in sex, age, education and employment status, alcohol and tobac-
co consumption, or weight. Sensitivity analysis using inverse
probability weighting to examine the effect in patient datasets
withmissing information did not showdifferent associations than
the presented model (see Table S1 in the supplementary
material).
Discussion
The introduction of antiretroviral medication has drastically
reduced morbidity and mortality. Although management of
HIV/AIDS cases through the use of ART has improved qual-
ity of life and a longer survival, chronic co-morbidities have
emerged. Also, increased life expectancy naturally made the
HIV-infected population grow older (Scanlon and Vreeman
2013; World Health Organisation 2015; UNAIDS 2016).
Hence, the continued high prevalence of sensory neuropathies
continues to affect PLHIVand requires clinical and health care
attention (Ellis et al. 2010; Schutz and Robinson-Papp 2013).
The present investigation including 525 patients is the largest
study on PN so far in Ghana and, to our knowledge, in West
Africa, carrying the highest burden of HIV infection worldwide.
In an earlier study, PN prevalencewas revealed in type 2 diabetes
patients in the same setting (Yeboah et al. 2016). The prevalence
of PN in this study’s subset of individuals admitted to the largest
tertiary referral hospital in Ghana in 2013/2014 and infected with
HIV/AIDS was 17.7%. This number somewhat ranges within
the ratios found in other studies performed in sub-Sahara
Africa. Such studies reported prevalence of 6% and 57% in
South Africa, respectively (Boulle et al. 2007; Wadley et al.
2011), 13% in Malawi (Beadles et al. 2009), 20.7% and 36%
in Kenya, respectively (Hawkins et al. 2007; Mehta et al. 2010),
36% in Uganda (Forna et al. 2007), 24% in Uganda/Zimbabwe
(Kiwuwa-Muyingo et al. 2014), 59% in Rwanda (Tumusiime
et al. 2014a), and 28% in Cameroon (Luma et al. 2012). A
recent study by Benevides et al. 2017 in southern Brazil unveiled
31.3% of PN prevalence in PLHIV. In some settings, variations
in the methodology to diagnose PN even seem to cause over-
reporting of PN (Tumusiime et al. 2014b).
These obvious differences may originate in the differing na-
ture of the performed studies: (i) the sample sizes differ consid-
erably, with our study representing a respectable patient number,
(ii) the inclusion criteria applied, resulting in varying average age
of the study subjects, (iii) varying progression stages of the un-
derlying HIV/AIDS infection of the study subjects, (iv) altering
diagnostic approaches and procedures applied, (v) the ratio of
Table 2 Descriptive statistics of
the administered ART regimen for
all subjects, stratified by PN status
Abbreviation ART regimen PN status All patients (n = 525)
n (%)
NRTI Nucleoside reverse transcriptase inhibitors No PN 218 (41.52)
PN 307 (58.47)
NNRTI Non-nucleoside reverse transcriptase inhibitors No PN 235 (44.76)
PN 290 (55.23)
PI Protease inhibitors No PN 512 (97.52)
PN 13 (2.476)
PN (peripheral neuropathy) = vibration perception threshold > 9 V, base of first toe (left and right; average of three
measurements)
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subjects being on antiretroviral medication, and (vi) the different
type of ART regimen administered to the study cohorts.
With regard to the latter, in many studies, patients were
enrolled whilst on NRTIs or protease inhibitors as a first-line
Table 3 Unadjusted associations
between peripheral neuropathy
(PN) and predicting
characteristics in HIV patients
(n = 525)
Characteristic PN (n = 93)
n (%)
No neuropathy (n = 432)
n (%)
p value*
Sex 0.433
Male 17 (18.3) 64 (15.1)
Female 78 (81.7) 361 (84.9)
Age (mean ± SD) 34.1 ± 4.8 33.5 ± 5.0 0.284
Education 0.147
None 13 (14.0) 75 (17.7)
≤ 9 years 55 (59.1) 198 (46.8)
9–12 years 21 (22.6) 102 (24.1)
> 12 years 4 (4.3) 46 (10.9)
Others 0 (0.0) 2 (0.5)
Employment status 0.392
Unemployed 15 (16.3) 89 (21.4)
Part-time 4 (4.3) 18 (4.3)
Full-time employment 69 (75.0) 296 (71.3)
Retired and not working 0 (0.0) 0 (0.0)
Retired but working 1 (1.1) 0 (0.0)
Lost employment when status was discovered 0 (0.0) 1 (0.24)
Too weak to continue working 3 (3.3) 11 (2.7)
Alcohol consumption 0.450
Yes, currently 7 (7.5) 45 (10.5)
No 86 (92.5) 383 (89.5)
Smoking status 0.222
Current smoker 0.0 10 (2.3)
Non/ex-smoker 93 (100.0) 419 (97.7)
Height (cm, mean ± SD) 1.7 ± 0.8 1.6 ± 0.8 < 0.001
Weight (kg, mean ± SD) 65.3 ± 14.5 63.1 ± 13.2 0.232
Waist girth (cm, mean ± SD) 57.1 ± 28.0 69.0 ± 26.3 0.002
Hip girth (cm, mean ± SD) 67.0 ± 31.7 81.7 ± 30.0 < 0.001
ART
Yes 50 (53.8) 264 (61.1) 0.201
No 43 (46.2) 168 (38.9)
CD4 cell count (mean ± SD) 407.3 ± 247.9 457.3 ± 276.4 0.236
Low-density lipoprotein (μmol/l, mean ± SD) 3.1 ± 0.9 3.2 ± 0.9 0.484
High-density lipoprotein (μmol/l, mean ± SD) 1.3 ± 0.5 1.3 ± 0.4 0.182
Lactate (mmol/l, mean ± SD) 1.9 ± 0.3 1.8 ± 0.4 0.072
Hemoglobin (g/dl, mean ± SD) 11.8 ± 1.7 11.9 ± 1.7 0.879
Neutrophils (cells/μl, mean ± SD) 41.1 ± 12.6 38.1 ± 11.7 0.033
Lymphocytes (cells/μl, mean ± SD) 48.5 ± 12.4 51.8 ± 11.9 0.020
Fasting glucose (mmol/l, mean ± SD) 4.7 ± 0.5 4.7 ± 0.6 0.795
Chromium (units, mean ± SD) 68.1 ± 23.5 62.6 ± 17.7 0.037
*Chi-square or Fisher’s exact test was used if characteristic was categorical and Mann-Whitney U test if
continuous
ART, antiretroviral therapy; SD, standard deviation
PN (peripheral neuropathy) = vibration perception threshold > 9 V, base of first toe (left and right; average of three
measurements)
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antiretroviral medication. It was repeatedly reported that these
drug groups have severe neurotoxic impact, above all stavu-
dine, but also didanosine and zalcitabine (Forna et al. 2007;
Hoffmann et al. 2008; Ances et al. 2009; Maritz et al. 2010;
Evans et al. 2011; Wadley et al. 2011; Kamerman et al. 2012;
Chen et al. 2013; Kiwuwa-Muyingo et al. 2014; World Health
Organisation 2015). In Ghana, since inception of the study, the
first-line treatment is a combination of two NRTIs and one
non-NRTI, followed by a second-line treatment also including
a protease inhibitor.
Increased CD4 counts may account for either immunocom-
petence or viral control due to treatment. Studies on subject
under NRTI treatment regimen usually did show low CD4
levels associated with PN whereas later studies, omitting
NRTIs and protease inhibitors, tend to show no association
between CD4 counts and sensory neuropathies (Evans et al.
2011; Benevides et al. 2017). The underlying mechanisms are
unclear and require additional research. Our unusual finding
of increased CD4 lymphocytes associated with PN only in
HIV infected on ART but not in non-treated patients remains
an undecided observation and may be interpreted such that the
treatment reduces viral load but continues to negatively affect
patients’ nervous conditions.
It was reported earlier that women are more affected by
development of PN (Collins et al. 2009; Nwabueze et al.
2012; Gomez-Olive et al. 2013; Kimanga et al. 2014;
Fagbamigbe et al. 2016) which is confirmed in this study.
Nevertheless, this does not necessarily mean that women are
more susceptible to development of PN. Women’s more pru-
dent health care–seeking behavior when confronted with ill-
ness, accounting for a higher detection rate in women, is a
likely explanation for this finding.
Accordingly, higher education usually leads to better
awareness of both a healthy lifestyle and handling of illness
including compliance to medication, and this coincides with
this study’s findings of a lower risk of PN development in
patients with higher education status. Surely, this association
supports the aspirations of the sustainable development goals
no. 1 Bno poverty,^ no. 4 Bquality education,^ and no. 10
Breduced inequalities^ also in this particular diseases.
Fig. 1 PN odd ratios (OR) for
patients on ART (yes vs. no) with
calculated predicted probability of
having PN in relation to CD4 cell
counts (adjusted for relevant
factors as shown in Table 4). Top
panel: OR of diagnosed PN in
patients on ART at different CD4
cell counts (knots show the OR;
whiskers the 95% CIs). Bottom
panel: effect of the interaction
between being on ART and CD4
cell counts on the PN-predicted
probability (calculated at the
mean values of 65.05 for waist
girth, 77.04 for hip girth, lactate <
2.2 mmol/l, a height < 1.57 m,
and education of < 9 years)
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Our study revealed that increasing height was independently
associated with the risk of developing of PN, reconfirming the
findings of other studies. This is probably simply owing to the
fact that increased nerve length, and thus a larger axon surface
area,may be of greater risk for neurological damage (Cheng et al.
2006; Chen et al. 2013; Kote et al. 2013; Luma et al. 2018).
In contrast to the recently published linkage between use of
tobacco and PN development in Brazil (Benevides et al.
2017), our data does not confirm such association.
Age as a risk factor for PN, however, was reported many
times before and proved to be so in HIV patients above 34 years
of our cohort as well (Evans et al. 2011; Wadley et al. 2011;
Nwabueze et al. 2012; Chen et al. 2013; Kiwuwa-Muyingo
et al. 2014; Tumusiime et al. 2014a, b). As possible explanation,
on the one hand, aging increases vulnerability towards neuronal
toxicity, on the other hand is the HIV population’s median age
rapidly increasing due to continuously improved management of
infected persons in Sub-SaharaAfrica, and so is the prevalence of
PN. Therefore, these results encourage health systems to routine-
ly screen PLHIV for early onset PN of age > 30 years.
The here determined association between PN in HIV patients
with levels of chromium (Head 2006; Kallianpur et al. 2006;
Afridi et al. 2014) and lactate (Miller et al. 2002; Brew et al.
2003) as well as elevated counts of neutrophils as compared to
CD4 lymphocytes (Ford et al. 2015; Means et al. 2016) indicates
that blood testing including these parameters may be a good
indicator when assessing early onset development of PN.
Meanwhile, genetic studies made assumptions on single-
nucleotide polymorphisms, i.e., in gene CAMKK2, on position
rs28445017, or in MTND2*LHON-4917G but possibly also
others, being associated with development of PN but this needs
further clarification (Canter et al. 2008; Wadley et al. 2015;
Goullee et al. 2016; Hendry et al. 2016; Gaff et al. 2018).
Surely, our study had limitations. The cross-sectional design
of our study did not allow for detecting PN prior to ART initia-
tion nor for longitudinal comparison between antiretroviral naïve
PLHIV and those on ART. Vibratory sense deficits may be
caused also by other factors whichmay have confounding effects
to the results. Only a few of our study participants were on
protease inhibitor–based regimen so that the influence of this
drug class may be undervalued. Difficult to quantify during the
interview and thus equally underestimated is substance con-
sumption (alcohol and tobacco). Since patients in the geographic
setting usually seek medical attention late, also the information
on the mean duration of HIV infection may be inaccurate. And
finally, confounding effects with i.e., cell folate deficiency, thy-
roid dysfunction, hepatitis B and C infection, paraproteinemia,
and any other potentially neurotoxic drugs cannot be entirely
ruled out in the study approach.
During the investigational period, we felt vindicated by our
approach of using the biothesiometer as a quantitative method
to determine PN for comparative diagnosis. However, during
the analyses phase, we sensed that complementing method(s)
could have underpinned the case definition and hence the
identified prevalence. We assumed both specificity and sensi-
tivity of above 70%; however, reports reveal a wider range
(England et al. 2005; Gill et al. 2014). In our view, the
biothesiometer should be accompanied by the observatory
clinical assessment of PN, the application of the monofilament
methodology, or even the Michigan neuropathy screening
Table 4 Multivariable* association of PN with ART and other risk factors (n = 333)
Risk factor Value/level Adjusted odd ratio 95% CI for OR p value
Intercept 0.010
On ART medication Yes vs. no, at CD4 = 600 cells 2.17 0.93 to 5.05 0.066
Interaction of on ART and CD4 cell count 0.007
CD4 cell count 10-unit increase for on ART 1.01 1.00 to 1.03 0.033
10-unit increase for not on ART 0.98 0.97 to 1.00
Lactate > 2.2 vs. ≤ 2.2 mmol/l 2.49 0.92 to 6.72 0.073
Age group > 34 years vs. ≤ 34 years 1.58 0.88 to 2.83 0.124
Education group (years of school) > 9 years vs. ≤ 9 years 0.49 0.26 to 0.92 0.027
Patient’s height (quartiles)§ > 1.66 vs. ≤ 1.57 m 5.74 2.11 to 15.62 < 0.001
> 1.62 to 1.66 vs. ≤ 1.57 m 4.89 1.69 to 13.66 0.003
> 1.57 to 1.62 vs. ≤ 1.57 m 3.84 1.38 to 10.66 0.010
Average waist girth 1-cm increase 1.04 0.98 to 1.09 0.159
Average hip girth 1-cm increase 0.96 0.92 to 1.00 0.054
*A logistic regression model was used. The original model included in addition the factors: change of ART medication, patient’s sex, alcohol intake,
height to weight ratio, and neutrophils and lymphocyte counts. Themodel was reduced using backwards selection excluding factors with a p value > 0.25
§ p = 0.007 for the overall effect of height
ART, antiretroviral therapy
PN (peripheral neuropathy) determined with vibration perception threshold > 9 V (base of first toe, left and right; average of three measurements)
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instrument (MNSI) which combines both symptoms and clin-
ical examinations and had been validated by earlier studies to
be accurate and reliable for screening PN (England et al. 2005;
Yajnik et al. 2012; Gill et al. 2014;Woldeamanuel et al. 2016).
Conclusions
Derived from the observation during our routine clinical man-
agement of HIV-PN patients admitted to the Korle-Bu
Teaching Hospital in Accra, Ghana, our assumption of a rela-
tively high prevalence of PLHIV developing PN was in a way
confirmed albeit the situation is less severe than presumed.
Possibly, the phasing out of the NRTIs didanosine, stavudine,
and zalcitabine in ART regulations by the Division of Public
Health under Ghana Health Service in 2012/2013 fortunately
reduced incidences of sensory neuropathies. Our results en-
dorse inclusion of safer ART regimens, known to have less
severe secondary effects, in respective national antiretroviral
regulations and continuation of developing and testing better
tolerable drugs against HIV infections.
The unveiled associations of PNwith demographic, anthro-
pometric, behavioral, and laboratory parameters confirmed
earlier findings, above all body height and age from 34 years
on as risk factors.
Our CD4 cell monitoring results, showing PN development
associated with CD4 lymphocyte increase only triggered by
ART but not in non-treated PLHIV, may hint towards possible
antiretroviral secondary effects. Such would need to be particu-
larly looked at in the sub-Saharan African setting which bears
among the highest HIV/AIDS disease burden.
The biothesiometer is a reliable tool for quantitative PN
diagnosis albeit the need for more robust and comparable
assessment remains obvious.
The prevalence of still 17.7% of PN among PLHIV indi-
cates that there is still a need for further reduction in morbidity
of neuronal damage even in the post-stavudine era.
Inacceptable complications, adding to the disability of the
affected, can be counteracted with surveillance, early identifi-
cation, and case management, requiring continued attention
by the health system. Early health care seeking should be
encouraged for both men and women, and PLHIV from the
age of 30 on should be routinely screened for PN.
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